{"id":8607,"date":"2025-11-24T23:02:20","date_gmt":"2025-11-24T23:02:20","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/11\/24\/biotech-news-can-a-glp-1-drug-slow-alzheimers\/"},"modified":"2025-11-24T23:02:20","modified_gmt":"2025-11-24T23:02:20","slug":"biotech-news-can-a-glp-1-drug-slow-alzheimers","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/11\/24\/biotech-news-can-a-glp-1-drug-slow-alzheimers\/","title":{"rendered":"STAT+: Lilly hits trillion-dollar valuation as GLP-1 era peaks"},"content":{"rendered":"<p>    STAT+: Lilly hits trillion-dollar valuation as GLP-1 era peaks<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p><em>Want to stay on top of the science and politics driving biotech today?\u00a0<a href=\"https:\/\/www.statnews.com\/signup\/readout\/\">Sign up<\/a>\u00a0to get our biotech newsletter in your inbox.<\/em><\/p>\n<p>Morning! We\u2019re closing in on CMS\u2019s deadline for 2027 Medicare-negotiated drug prices. Plus, we see a break from precedent\u00a0in how the FDA selects priority review vouchers, and more.\u00a0<\/p>\n<h2 class=\"wp-block-heading\" id=\"h-can-a-glp-1-drug-slow-alzheimer-s-disease-nope\">Can a GLP-1 drug slow Alzheimer\u2019s disease? Nope<\/h2>\n<p>Novo Nordisk said this morning\u00a0that a pair of large, placebo-controlled clinical trials testing an oral version of its GLP-1 drug semaglutide failed to slow the cognitive decline of participants with Alzheimer\u2019s disease.<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2025\/11\/24\/biotech-news-can-a-glp-1-drug-slow-alzheimers\/?utm_campaign=rss\">Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Meghana Keshavan<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/2025\/11\/24\/biotech-news-can-a-glp-1-drug-slow-alzheimers\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>STAT+: Lilly hits trillion-dollar valuation as GLP-1 era peaks Want to stay on top of the science and politics driving biotech today?\u00a0Sign up\u00a0to get our biotech newsletter in your inbox. Morning! We\u2019re closing in on CMS\u2019s deadline for 2027 Medicare-negotiated drug prices. Plus, we see a break from precedent\u00a0in how the FDA selects priority review [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2194,2154,58,2208,2209,2176,858,2207],"tags":[2150],"class_list":["post-8607","post","type-post","status-publish","format-standard","hentry","category-biotech","category-biotechnology","category-business","category-drug-development","category-drug-prices","category-pharma","category-research","category-the-readout","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/8607"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=8607"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/8607\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=8607"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=8607"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=8607"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}